BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26334953)

  • 1. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
    Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
    Nucleic Acid Ther; 2015 Dec; 25(6):317-22. PubMed ID: 26334953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
    Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
    PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex.
    Subramanian N; Kanwar JR; Athalya PK; Janakiraman N; Khetan V; Kanwar RK; Eluchuri S; Krishnakumar S
    J Biomed Sci; 2015 Jan; 22():4. PubMed ID: 25576037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-walled carbon nanotubes functionalized with aptamer and piperazine-polyethylenimine derivative for targeted siRNA delivery into breast cancer cells.
    Mohammadi M; Salmasi Z; Hashemi M; Mosaffa F; Abnous K; Ramezani M
    Int J Pharm; 2015 May; 485(1-2):50-60. PubMed ID: 25712164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.
    Subramanian N; Raghunathan V; Kanwar JR; Kanwar RK; Elchuri SV; Khetan V; Krishnakumar S
    Mol Vis; 2012; 18():2783-95. PubMed ID: 23213278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells.
    Gilboa-Geffen A; Hamar P; Le MT; Wheeler LA; Trifonova R; Petrocca F; Wittrup A; Lieberman J
    Mol Cancer Ther; 2015 Oct; 14(10):2279-91. PubMed ID: 26264278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.
    Wang T; Gantier MP; Xiang D; Bean AG; Bruce M; Zhou SF; Khasraw M; Ward A; Wang L; Wei MQ; AlShamaileh H; Chen L; She X; Lin J; Kong L; Shigdar S; Duan W
    Theranostics; 2015; 5(12):1456-72. PubMed ID: 26681989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging.
    Roy K; Kanwar RK; Kanwar JR
    Biomaterials; 2015 Dec; 71():84-99. PubMed ID: 26318819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
    Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
    Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer.
    Alibolandi M; Ramezani M; Abnous K; Sadeghi F; Atyabi F; Asouri M; Ahmadi AA; Hadizadeh F
    J Control Release; 2015 Jul; 209():88-100. PubMed ID: 25912964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture.
    Song Y; Zhu Z; An Y; Zhang W; Zhang H; Liu D; Yu C; Duan W; Yang CJ
    Anal Chem; 2013 Apr; 85(8):4141-9. PubMed ID: 23480100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.
    Osta WA; Chen Y; Mikhitarian K; Mitas M; Salem M; Hannun YA; Cole DJ; Gillanders WE
    Cancer Res; 2004 Aug; 64(16):5818-24. PubMed ID: 15313925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric aptamers in cancer cell-targeted drug delivery.
    Kanwar JR; Roy K; Kanwar RK
    Crit Rev Biochem Mol Biol; 2011 Dec; 46(6):459-77. PubMed ID: 21955150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
    McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
    Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.
    Bagalkot V; Gao X
    ACS Nano; 2011 Oct; 5(10):8131-9. PubMed ID: 21936502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
    Sivakumar P; Kim S; Kang HC; Shim MS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge.
    Zhou J; Rossi JJ; Shum KT
    Methods Mol Biol; 2015; 1297():169-85. PubMed ID: 25896003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.
    Mook OR; Baas F; de Wissel MB; Fluiter K
    Mol Cancer Ther; 2007 Mar; 6(3):833-43. PubMed ID: 17363479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule.
    Shigdar S; Lin J; Yu Y; Pastuovic M; Wei M; Duan W
    Cancer Sci; 2011 May; 102(5):991-8. PubMed ID: 21281402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strain-promoted alkyne-azide cycloaddition (SPAAC) reaction of a novel EpCAM aptamer-fluorescent conjugate for imaging of cancer cells.
    Subramanian N; Sreemanthula JB; Balaji B; Kanwar JR; Biswas J; Krishnakumar S
    Chem Commun (Camb); 2014 Oct; 50(80):11810-3. PubMed ID: 25005751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.